XXIIIA

Simoons ML, Decker JW: New directions in anticoagulant and antiplatelet treatment.
[Editorial.] Br Heart J 1995;74:337.)
Simoons ML, Decker JW: New directions in anticoagulant and antiplatelet treatment.
[Editorial.] Br Heart J 1995;74:337.)

Simoons ML, Decker JW: New directions in anticoagulant and antiplatelet treatment. [Editorial.]
Br Heart J 1995;74:337.)

Simoons ML, Decker JW: New directions in anticoagulant and antiplatelet treatment.
[Editorial.] Br Heart J 1995;74:337.)

ROLE OF PLATELETS IN ARTERIAL THROMBOSIS
Jeffrey I. Weit. Antiplatelet, Anticoagulant, and Fibrinolytic. Drugs. Harisson 17
th
edition.
SITE ACTION OF ANTIPLATELET DRUG
Jeffrey I. Weit. Antiplatelet, Anticoagulant, and Fibrinolytic. Drugs. Harisson
17
th
edition.
Jeffrey I. Weit. Antiplatelet, Anticoagulant, and Fibrinolytic. Drugs. Harisson
17
th
edition.
ANTICOAGULAN

Jeffrey I. Weit. Antiplatelet, Anticoagulant, and Fibrinolytic. Drugs. Harisson
17
th
edition.
Jeffrey I. Weit. Antiplatelet, Anticoagulant, and Fibrinolytic. Drugs. Harisson
17
th
edition.
Jeffrey I. Weit. Antiplatelet, Anticoagulant, and Fibrinolytic. Drugs. Harisson
17
th
edition.
FIBRINOLITIK
Jeffrey I. Weit. Antiplatelet, Anticoagulant, and Fibrinolytic. Drugs. Harisson
17
th
edition.
Plasmino-gen activators convert plasminogen to plasmin. Plasmin
then de-grades fibrin into soluble fibrin degradation products. The
system is regulated at two levels. Type 1 plasminogen activator
inhibitor (PAI-1) regulates the plasminogen activators, whereas 2-
antiplasmin serves as the major inhibitor of plasmin.
Jeffrey I. Weit. Antiplatelet, Anticoagulant, and Fibrinolytic. Drugs. Harisson
17
th
edition.